相关实验视频

Updated: Jan 10, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

固体瘤治疗中的GLP-1受体激活剂:探索它们的抗癌潜力和潜在的分子通路

Daniela Lucente¹, Stefania Bellino¹, Anna La Salvia¹

¹National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy.

|November 27, 2025

概括

类似葡萄糖-1受体激动剂 (GLP-1RA) 通过调节关键通路,在临床前癌症模型中显示出潜在的抗瘤作用. 需要进一步的临床研究来证实它们在固体瘤中的治疗作用.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

类似葡萄糖类-1受体激动剂 (GLP-1RA) 是已确立的2型糖尿病治疗方法.
新兴研究正在探索GLP-1RA在各种固体恶性瘤中的潜在抗癌特性.

研究的目的:

批判性地审查GLP-1RA在癌症中的分子机制.
评估它们的抗瘤活性和潜在的致性问题.

主要方法:

对癌症GLP-1RA的临床前研究 (体外和体内) 的综述.
通过GLP-1RA调节的分子通路的分析,包括PI3K/Akt,PKA和AMPK.
检查对癌细胞增殖,细胞亡,血管生成和炎症的影响.

主要成果:

临床前数据表明GLP-1RA具有抗瘤活性,抑制瘤生长和转移.
GLP-1RA调节关键信号通路并产生抗炎作用.
对特定癌症类型的潜在瘤发生作用的担忧仍然存在.

结论:

GLP-1RA通过各种分子机制显示出临床前的抗瘤潜力.
进一步的临床研究对于确定GLP-1RA在瘤学中的治疗相关性至关重要.
在管理固体瘤方面,GLP-1RA可被视为辅助剂.

关键词:

作为GLP-1受体的激动剂.它具有抗瘤活性.炎症和癌症的发生.分子机制的分子机制.固体瘤是指固体瘤中的瘤.

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...